BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 23464464)

  • 1. Human epididymis protein 4 reference intervals in a multiethnic asian women population.
    Mokhtar N; Thevarajah M; Ma N; M I
    Asian Pac J Cancer Prev; 2012; 13(12):6391-5. PubMed ID: 23464464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The reference intervals for HE4, CA125 and ROMA in healthy female with electrochemiluminescence immunoassay.
    Yang J; Sa M; Huang M; Yang J; Xiang Z; Liu B; Tang A
    Clin Biochem; 2013 Nov; 46(16-17):1705-8. PubMed ID: 24012857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Epididymis Protein 4 (HE4) Reference Limits in Polish Population of Healthy Women, Pregnant Women, and Women with Benign Ovarian Tumors.
    Gasiorowska E; Kluz T; Lipski D; Warchoł W; Tykarski A; Nowak-Markwitz E
    Dis Markers; 2019; 2019():3890906. PubMed ID: 31583027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer.
    Park Y; Kim Y; Lee EY; Lee JH; Kim HS
    Int J Cancer; 2012 Mar; 130(5):1136-44. PubMed ID: 21484794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis.
    Suri A; Perumal V; Ammalli P; Suryan V; Bansal SK
    Sci Rep; 2021 Aug; 11(1):17308. PubMed ID: 34453074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age and menopausal status are important factors influencing the serum human epididymis secretory protein 4 level: a prospective cross-sectional study in healthy Chinese people.
    Cheng HY; Zeng L; Ye X; Ma RQ; Tang ZJ; Chu HL; Zhao YM; Zhu LR; Gao YN; Chang XH; Cui H
    Chin Med J (Engl); 2020 Jun; 133(11):1285-1291. PubMed ID: 32404690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age.
    Moore RG; Miller MC; Eklund EE; Lu KH; Bast RC; Lambert-Messerlian G
    Am J Obstet Gynecol; 2012 Apr; 206(4):349.e1-7. PubMed ID: 22301440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer.
    Dikmen ZG; Colak A; Dogan P; Tuncer S; Akbiyik F
    Eur J Gynaecol Oncol; 2015; 36(4):457-62. PubMed ID: 26390703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of reference intervals of serum levels of human epididymis protein 4 (HE4) in Chinese women.
    Tian Y; Wang C; Cheng L; Zhang A; Liu W; Guo L; Ye H; Huang Y; Chen J; Wen X; Xing Y; Zheng G; Sun Z; Li H; Zhang P; Liu W; Chen Y; Zhang Z; Xu Y; Huo Y; Ou Q
    J Ovarian Res; 2015 Nov; 8():72. PubMed ID: 26552478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does HE4 have a role as biomarker in the recurrence of ovarian cancer?
    Plotti F; Capriglione S; Terranova C; Montera R; Aloisi A; Damiani P; Muzii L; Scaletta G; Benedetti-Panici P; Angioli R
    Tumour Biol; 2012 Dec; 33(6):2117-23. PubMed ID: 22875782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determination of the Reference Values of the Tumor Marker HE4 in Female Population of Canton Sarajevo.
    Hasanbegovic L; Sljivo N
    Mater Sociomed; 2018 Mar; 30(1):15-19. PubMed ID: 29670473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The diagnostic accuracy of human epididymis protein 4 (HE4) for discriminating between benign and malignant pelvic masses: a systematic review and meta-analysis.
    Olsen M; Lof P; Stiekema A; van den Broek D; Wilthagen EA; Bossuyt PM; Lok CAR
    Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1788-1799. PubMed ID: 34212386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The differential diagnostic value and clinical significance of serum HE4 in ovarian disease with elevated CA125.
    Li W; Wang D
    Arch Gynecol Obstet; 2020 May; 301(5):1219-1225. PubMed ID: 32266526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management.
    Bandiera E; Romani C; Specchia C; Zanotti L; Galli C; Ruggeri G; Tognon G; Bignotti E; Tassi RA; Odicino F; Caimi L; Sartori E; Santin AD; Pecorelli S; Ravaggi A
    Cancer Epidemiol Biomarkers Prev; 2011 Dec; 20(12):2496-506. PubMed ID: 22028406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Revised Cut-Off Value of Human Epididymis Protein 4 Enhances Its Use as an Ovarian Tumor Marker.
    Machida H; Hirakawa T; Tsunekawa K; Kimura T; Murakami M; Abe Y
    Gynecol Obstet Invest; 2023; 88(6):349-358. PubMed ID: 37788640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer.
    Urban N; Thorpe J; Karlan BY; McIntosh MW; Palomares MR; Daly MB; Paley P; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2012 Nov; 21(11):2087-94. PubMed ID: 22962406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women.
    Yu S; Lee JK; Kim JH; Park H; Lee MY; Ryu S; Kwon MJ; Woo HY
    Gynecol Oncol; 2016 Oct; 143(1):128-134. PubMed ID: 27426308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HE4 combined with CA125: favorable screening tool for ovarian cancer.
    Ghasemi N; Ghobadzadeh S; Zahraei M; Mohammadpour H; Bahrami S; Ganje MB; Rajabi S
    Med Oncol; 2014 Jan; 31(1):808. PubMed ID: 24323399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response.
    Hamed EO; Ahmed H; Sedeek OB; Mohammed AM; Abd-Alla AA; Abdel Ghaffar HM
    Diagn Pathol; 2013 Jan; 8():11. PubMed ID: 23343214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.